 In another interview with Business Week and CBS, Armen described how the idea of personalized medicine tailored to the patient led to his launching Antigenics with $250,000 of his own money, plus the backing of a few friends.He was initially stirred by the results from animal testing; the vaccine cured 80% of mice in the early stages of cancer with virtually no side effects.By February 2000, Antigenics went public at $18 a share, raising $72.5 million.